Archive for the ‘Basal cell carcinoma’ Category
Eggplant news, articles and information
(NaturalNews) An ingredient in common eggplant has been shown to cure cancer. The eggplant extract is a phytochemical called solasodine glycoside, or BEC5. Dr. Bill E. Cham discovered it, after hearing of a folk medicine cure from Australian farmers. They told him of eye cancers cured in cattle after application of a poultice made from the fruit of a weed called Devil”s Apple, known in Latin as Solanum linnaeanum. This plant is part of the Solanacea family, which includes other common vegetables such as tomato and eggplant.
Actinic keratoses are a possible predictor of skin cancer. These red patches caused by sun exposure are made of abnormal cells that can mutate intomalignant cells in the basal, or lower layers of the skin. Squamous cell carcinomas are another common form of skin cancer and one which causes nearly two thousands deaths annually. This wart-type growth has irregular borders and can also be treated with the eggplant extract.
Used as a cream for over twenty-five years in clinical trials in both Australia and the United Kingdom, BEC5 had success rate of over 78% when applied for eight weeks. Used for 12 weeks, the cream had a 100% success rate in removing cancers, none of which returned for the following five years.
Over one million new cases of non-melanoma skin cancers are diagnosed each year in the United States alone. Skin cancer is now the most common illness in men over the age of 50. It is even more common than lung, prostate or colon cancer. Incidences are so common that one out of three Caucasians are now expected to develop skin cancer at some point in their lives. With this simple, natural remedy, many surgeries might be prevented and health restored.
Scientists have discovered that a phytochemical called solasodine glycoside, found in common fruits and vegetables like tomatoes and eggplant, has cancer-fighting properties. These properties have been discovered in natural substances before, but when extracted and developed into treatment therapies, they often prove ineffective.
Cham claims that Curaderm BEC5, which was inspired by Australian farmers” folk remedies, is a safe, effective topical medication that can kill diseased cells without harming healthy ones. If he is correct, this could be a landmark discovery for cancer research. One of the biggest battles medical researchers face is figuring out how to isolate and treat only unhealthy cells. Traditional radiation and chemotherapy treatments can have such damaging side effects because they target all cells. Compared to potentially disfiguring surgical procedures-the standard treatment for Basil- and Squanomous-Cell Carcinomas-this cream seems like a dream come true.
In 2006, Bill E. Cham, Ph.D., published a book in which he proposed that he was able to isolate this compound and develop it into the cream Curaderm BEC5. The cream could treat pre-cancerous lesions and the most common kinds of skin cancers.
Eggplant and Similar Plant Extracts Used for Treating Cancer Since 1825
There are reports that extracts of plants from the Solanaceae family of vegetables are effective for treating cancer dating back nearly 200 years to 1825, according to natural health pioneer Dr. Jonathan Wright. However, it wasn”t until much later, after the 1950s, that they were formally studied.
The leading researcher in this area today is Dr. Bill E. Cham, who reported as early as 1991 in Cancer Letters that:
“A cream formulation containing high concentrations (10%) of a standard mixture of solasodine glycosides (BEC) has been shown to be effective in the treatment of malignant and benign human skin tumors.
We now report that a preparation … which contains very low concentrations of BEC (0.005%) is effective in the treatment of keratoses, basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) of the skin of humans. In an open study, clinical and histological observations indicated that all lesions (56 keratoses, 39 BCCs and 29 SCCs) treated with [the preparation] had regressed.”
A subsequent study by separate researchers also noted that a 0.005% mixture of solasodine glycosides called BEC5 is a “safe therapy for basal cell carcinoma, with a cure rate of 66% at 8 weeks and 78% at 1 year follow-up.”
The findings are exciting, to say the least, because while basal cell and squamous cell carcinomas — the two most common types of skin cancer — are highly curable even by conventional medical standards, there are serious disadvantages with the common treatments. As Dr. Cham reported, the treatment and management of nonmelanoma skin cancers cost more than $1.4 billion per year in the United States, a number that is increasing exponentially each year and quickly becoming unsustainable.
Further, the common treatments, surgery and radiation therapy, pose the following problems:
- Surgery may not remove all cancerous cells
- Painful with slow healing
- Scarring often occurs, which can be cosmetically unappealing, especially if the cancer is on your face
- Serious health risks of radiation therapy
- High recurrence rates have been reported following conventional treatment
That affordable eggplant extract appears to effectively eliminate cancerous lesions with absolutely no scarring and only minor itching and burning as side effects is impressive.
To the Whom It May Concern:
Written by Dr. Bill Cham
The Department of Dermatology at the Royal Brisbane Hospital have previously reported in this Journal that Curaderm was not a satisfactory treatment for BCCs (1, 2). The deficiencies of their studies have previously been addressed (3). Curaderm contains lower concentrations of solasodine glycosides (BEC) than is found in edible fruit. In Australia, Curaderm has been approved for the indication of keratosis by prescription. . The product Curaderm is an effective topical cream for the treatment of keratosis, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) (4). Other published articles reported that solasodine glycosides from the plant genus Solanum, such as the devil’s apple, kangaroo apple and aubergine, have antineoplastic activities (4).
A multicentre, double blind, vehicle-controlled, randomised, parallel group study to assess the efficacy and safety of BEC 5 in the treatment of patients with BCC has now been completed. Instead of the brand name Curaderm, the preparation was termed BEC 5 in the clinical trial, because in Europe, another unrelated substance is registered as Curaderm. Curaderm and BEC5 essentially contain 50 mg of the active ingredient (BEC) per kg cream. All of the investigators were dermatologists (Table). Patients with BCCs applied the BEC 5 or vehicle cream twice daily for 8 weeks and were followed up for 14 months from the start of the treatment. The efficacy was defined by complete healing, confirmed by clinical and histological examination after 8 weeks ± 3 days of treatment. More BEC 5-treatment patients [41 out of 62 patients (66.1%)] were classed as successes than in the vehicle group of patients [8 out of 32 patients (25%)] at week 8 (p<0.001; Cochran-Mantel-Haenszyl test). BEC 5 was safe and generally well tolerated.
Subsequently, an open study comprising 41 patients was carried out at the Royal London Hospital. The trial included BEC 5 treatment of superficial and morpheoic (invasive) BCCs. The success rate of these lesions was 78%. The investigators concluded:
“BCC is a slow growing, locally invasive malignant skin tumour which mainly affects Caucasians. Dermatologists, plastic surgeons and radiotherapists jointly manage the afflictions. Such management usually involves surgery. The risks of surgical intervention are well known. Moreover, excision of BCC from the facial area often involves reconstructive surgery, which can be both time consuming and costly. Hence an alternative, safe and efficacious method of treatment of BCC that does not require physician or hospital attendance must be encouraged. In our view and experience BEC 5 is a topical preparation, which is safe and effective, ideal therapy for outpatient treatment. Hence BEC 5 is a much-needed alternative to surgery for BCC. It is a cost effective treatment for both primary and secondary skin care”.
The efficacy rates of the open trial paralleled the multi-centre efficacy rates. Success was defined as zero presence of BCC after histological examination of samples extracted from the lesion site by punch biopsy.
The results of these recent trials confirm the work with Curaderm published over a decade ago (4). In the earlier studies longer duration therapy, up to 13 weeks, resulted in removal of all BCC lesions that were treated.
To date no independent Phase III trials or open studies on SCC lesions have been conducted. However, earlier studies clearly indicate that Curaderm is also effective in eradicating SCC (4). The cosmetic end results of Curaderm-treated SCC lesions are very impressive. The Figure shows the clinical results of a Curaderm-treated pronounced SCC. No recurrence of the SCC lesion occurred after 5 years follow-up.
Our group predicated that the antineoplastic mode of action of the solasodine glycosides (BEC) was mediated through endocytic endogenous lectins (EELs) receptors on cancerous cells, culminating in lysosomotropic action of the solasodine glycosides resulting in tumour cell death (4). This hypothesis has been confirmed by independent groups (5) and is currently being widely investigated as a novel approach for cancer treatments.
In November 2003, approvals have been obtained to commence human clinical trials on internal cancers with solasodine glycosides at Sir Charles Gardiner Hospital in Perth, Western Australia. The approval of these trials is based on the promising antineoplastic, low toxicity results of the solasodine glycosides, obtained in human cell culture and whole animal studies (4).
This Phase I/IIa trial will evaluate the safety, tolerability and pharmacokinetics of solasodine glycosides in patients with advanced tumours such as mesothelioma and malignant melanoma.
In conclusion, the question regarding Curaderm – or is it? (2) Has now been answered
Curaderm – it sure is!
- Beardmore, G., Hart, V., Wilson, P. and Francis, D.B. (1989). Curaderm preliminary findings. Med. J. Australia, 150, 46 (Letter).
- Francis, D.B., Hart, V., Wilson, P. and Bearmore, G. (1989). Curaderm – or is it? Med. J. Australia, 151, 541-542 (Letter).
- Cham, B.E., Daunter, B. and Evans, R. (1990). Curaderm. Med. J. Austral. 152, 329-330.
- Cham, B.E. (1994). Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies. Asia Pacif. J. Pharmacol. 9, 113-118.
- Nakamura, T., Komori, C., Lee, Y., et al (1996). Cytotoxic activities of Solanum steroidal glycosides. Biol. Biopharm. Bull 19, 546-56
United Kingdom Hospitals Dermatologist Clinical Trial
Dermatology Department 2nd Floor Outpatient Building
Hospital White Chapel London, E1 1BB
Tuesday April 23rd 2002
CLINICAL APPRAISAL of BEC5
You have requested us to detail our clinical experience with BEC5 in the treatment of malignant lesions of the skin. We understand that this may be shown to potential purchasers of BEC5.
The Dermatology Department at the Royal London Hospital has acted as an approved and designated center in two clinical trials to determine the safety and efficacy of BEC 5 cream in the treatment of cancerous lesions of the skin. In the first of these, a pivotal double blind randomized study; Royal London recruited, treated and monitored 21 of the 94 patients. In the second trial, comprising 41 patients, Royal London was the sole designated centre. This trial was an open study, conducted primarily assess the safety of the product. Herewith we summarize our observation on the use, safety, efficacy, cosmetic result and resource effectiveness of the product.
The trials were formally restricted to patients diagnosed by physician as having superficial basal cell carcinoma. Hence patients with morpheoic lesions were excluded. However subsequently conducted punch biopsy results demonstrated that several trial patients did in deed have basal cell carcinoma. Even so our findings in respect of these patients were that successful treatment of the invasive form of basal cell carcinoma paralleled the general success rate of BEC5 ie, around 78%.
In our view these results, in the least justify a more extensive clinical trial of BEC5 against such cancers. We note in this respect that treatment of the morpheoic form of the affliction is presently confined to surgical removal. We are not aware of any emerging therapy, for example, photodynamic therapy that has the potential to extend to treatment of other than superficial skin cancers.
Our clinical experience has shown that BEC5 is safe. In the two frequent (twice daily) and prolonged (8 weeks) application of a cream incorporating BEC5 under occlusive dressing resulted only in local skin irritation and erythema. Very few patients under our supervision withdrew from treatment on this account. Hence we consider treatment with BEC5 to be safe therapy.
Furthermore, patient blood and urine was analyzed using very sensitive methods to determine the presence of the BEC5 during and after a standard treatment regime (twice daily for 8 weeks). Such analysis produced no evidence of the active pharmaceutical ingredients to BEC5 or their breakdown products. Hence, it was concluded that there is no systemic absorption of BEC5. This is extremely important from the clinical perspective and may be contrasted with other topical preparations. For example, 5 fluouracil shows systemic absorption and can prove to be toxic when used with large lesions.
Royal London has a large dedicated skin cancer clinic as it is a Skin Cancer Center for the North East Thames Network. This fact, coupled with the results of the first trial, was instrumental on Royal London”s conduct of second open study. Success rates in this open trial paralleled the multi-center efficacy rate of 78%. Success was defined as zero presence of basal cell carcinoma after histological examination of samples extracted from the lesion site by punch biopsy.
We consider that this rate of treatment success more than justifies the physician considering BEC5 as an alternative to currently predominant treatment such as surgical excision or cryotherapy.
BEC results in ulceration of the lesion site during treatment. However, we have observed that post treatment the wound is quickly replenished with normal tissue and that residual scarring is minimal. Whether such scarring proves more or less extensive than that consequent upon surgical excision is dependant on a number of factors including lesion size, location and so on. However, it can be said that the cosmetic results offered by treatment with BEC5 are comparable to that resulting from surgical excision.
Basal Cell Carcinoma is a slow growing locally invasive malignant skin tumor which mainly affects Caucasians. Dermatologists, plastic surgeons and radiotherapists jointly manage the affliction, such management usually involves surgery. The risks of surgical intervention are well known.
Moreover, excision of basal cell carcinoma from the facial area often involves reconstructive, which can be both time consuming and costly. Hence an alternative, safe and efficacious method of treatment of basal cell carcinoma that does not require physician or hospital attendance must be encouraged.
In our view and experience BEC5 is a topical preparation, which is safe and effective, ideal therapy for outpatient treatment. Hence BEC5 is a much needed alternative to surgery for basal cell carcinoma. This is the commonest cancer in Caucasians worldwide and the prevalence continues to increase with an increasing ageing population. It is a cost effective treatment for both primary and secondary skin cancer care.
We trust that the following is adequate for your purposes
Rino Cerio BS (Lond) FRCP (Edin) FRCPath Consultant Dermatologist and Senior Lecturer in Dermatopathology
Dr. Sangeeta Punjabi MBBS, DVD, DipNB (Dermatology) Research Registrar, Royal London Hospital
NOTE: This is a transcript of the clinical evaluation of by
Barts And The London NHS – NHS Trust
Curaderm BEC5 is also a cream used to treat superficial Basal Cell Carcinomas, and is made up of 99.8% natural ingredients. The active ingredient in Curaderm BEC5 is 0.005% Solasodine Glycoside which is extracted from Aubergines (Egg plants) and a plant called Devil”s Apple (in Latin, Solanum linnaeanum).
I first noticed a small red mark (less than 1 cm) on my forehead about 7 years ago. I wasn”t concerned about it and so didn”t seek any medical advice. About 5 years ago the mark was still there and slightly bigger so I decided to see a dermatologist who prescribed Efudix cream. The cream didn”t seem to have any effect so I stopped using it.
After doing nothing about the Basal Cell Carcinoma for a further couple of years I decided to see another dermatologist who said that surgery was the only way to get rid of the Basal Cell Carcinomaas it was so large. I did all the regular examinations before the surgery (blood test, x-rays etc..) but then just before the scheduled surgery I got another job which meant I was away from home 6 days a week, so I didn”t do the surgery.
After another year (I managed to get a better job closer to home) I went back to the same dermotologist who (after severely repremanding me) sent me to a specialist cancer clinic.
It was at about this time, after researching alternatives to surgery for my Basal Cell Carcinoma, I came across Curaderm BEC5.